Mets from BC- multigene testing for targeted therapy?

Portal Forums Breast Cancer Breast Cancer Key Issues Molecular/Genetic Factors Mets from BC- multigene testing for targeted therapy?

This topic contains 1 reply, has 2 voices, and was last updated by JimC Forum Moderator JimC Forum Moderator 2 months ago.

Viewing 2 posts - 1 through 2 (of 2 total)
Author Posts   
Author Posts
June 12, 2018 at 1:23 am  #1294619    

Hey, everyone!

I’m writing as my mom (60, lung and some bone mets from breast cancer, now over 2nd line chemo with Taxol after Faslodex failed) is looking at multigene testing to see what therapy can work next (I’m not sure I am writing this down right). Obviously, the insurance won’t cover it, it’s super expensive and once we have the results, the drugs recommended might not even be in our country (Romania), and we won’t be able to afford to go elsewhere. Has anyone done more testing on their tumor? (other than the hormone receptors)? Is it worth it? I’d love to hear about your experiences!

Many thanks and hugs to you, inspiring community!

June 12, 2018 at 6:39 am  #1294620    
JimC Forum Moderator
JimC Forum Moderator

Hi bravesocks,

Multigene testing has been shown to have value for some purposes, such as assessing hereditary risk of breast cancer as well as the risk of relapse. But in terms of predicting which treatments are more likely to be effective, the evidence is not yet strong enough to warrant much confidence in such predictions (other than specific mutations for which there exist targeted therapies). As stated in this article from Breast Cancer Research:

…drug-specific treatment response predictors also remain elusive. Emerging areas of research involve the development of immune gene signatures that carry modest but significant prognostic value independent of proliferation and ER status and represent candidate predictive markers for immune-targeted therapies. Overall metrics of tumor heterogeneity and genome integrity (for example, homologue recombination deficiency score) are emerging as potential new predictive markers for platinum agents. The recent expansion of high-throughput technology platforms including low-cost sequencing of circulating and tumor-derived DNA and RNA and rapid reliable quantification of microRNA offers new opportunities to build extended prediction models across multiplatform data. (with free registration, you can view the entire article).

So unfortunately at this point, using multigene testing to choose a therapeutic agent is still a work in progress.

Forum moderator

Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Tarceva maintenance
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then:

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.